Akari

AKTX NASDAQ
2.764
+0.004
+0.14%
交易中 10:59 05/20 EDT
开盘
2.720
昨收
2.760
最高
2.779
最低
2.650
成交量
1.81万
成交均量(3M)
245.48万
52周最高
9.20
52周最低
1.560
换手率
0.11%
市值
4,368.72万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供Akari AKTX股票价格,Akari股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.
展开 >

最近浏览

名称
价格
涨跌幅